Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Oncologist. 2021 Oct;26(10):e1880-e1882. doi: 10.1002/onco.13910. Epub 2021 Aug 11.
The Oncology Center of Excellence at the U.S. Food and Drug Administration launched Project Facilitate on May 31, 2019, to assist oncology health care providers with Expanded Access requests for investigational drugs. Expanded Access, sometimes called "compassionate use," is a regulatory pathway for physicians caring for patients who have a life-threatening condition or a serious disease to gain access to an investigational drug for treatment when no comparable or satisfactory alternative treatment options are available. Herein we describe the Project Facilitate program and the process for requesting Expanded Access to an investigational drug.
美国食品和药物管理局(FDA)肿瘤卓越中心于 2019 年 5 月 31 日启动了“项目协助”(Project Facilitate),旨在帮助肿瘤医疗保健提供者处理扩大准入(Expanded Access)的研究性药物申请。扩大准入,有时也被称为“同情使用”,是为治疗患有危及生命的疾病或严重疾病的患者而提供的一种监管途径,当没有可比或令人满意的替代治疗方案时,医生可以获得研究性药物的治疗。本文描述了“项目协助”计划以及请求扩大准入研究性药物的流程。